PBP — Probiotec Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedSmall Cap
- AU$242.34m
- AU$315.62m
- AU$214.03m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.95 | ||
| PEG Ratio (f) | 1.44 | ||
| EPS Growth (f) | 11.58% | ||
| Dividend Yield (f) | 2.35% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.74 | ||
| Price to Tang. Book | 57.11 | ||
| Price to Free Cashflow | 50.39 | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | 9.21 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7% | ||
| Return on Equity | 10.18% | ||
| Operating Margin | 5.87% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 73.24 | 107.22 | 120.51 | 182.33 | 214.03 | 238.4 | 252.7 | 23.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -25.06 | +66.71 | -61.76 | +393.23 | -24.56 | +31.6 | +11.11 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Probiotec Limited is an Australia-based manufacturer, packer and distributor of a range of prescription and over the counter (OTC) pharmaceuticals, complementary medicines, consumer health products, and fast-moving consumer goods (FMCG). The Company owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. It offers full-service contract manufacturing and packing. The Company manufactures products on behalf of a range of clients, including international pharmaceutical companies. The Company services blue-chip manufacturers, multinational FMCG companies, local manufacturers and brand custodians. All types of FMCG products are packed or handled, such as canned food, alcohol, tea and coffee, dairy and frozen foods, sauces and condiments, and bottled water. Its subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Multipack-LJM Pty Ltd, LJM (NSW) Pty Ltd and HH Packaging Pty Ltd.
Directors
- Jonathan Wenig CHM
- Wesley Stringer CEO
- Jared Stringer CFO
- Mark Chatfield GMG
- Dustin Stringer GMG
- Humera Ahmad OTH
- Scott Patterson OTH
- Simon Gray NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 8th, 1996
- Public Since
- November 14th, 2006
- No. of Shareholders
- 2,054
- No. of Employees
- 111
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 81,323,406
- Address
- 83 Cherry Lane, Laverton North, MELBOURNE, 3026
- Web
- http://www.probiotec.com.au/
- Phone
- +61 393696730
- Auditors
- ShineWing Australia
Upcoming Events for PBP
Probiotec Ltd Annual Shareholders Meeting
Similar to PBP
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Probiotec share price?
As of Today at 22:46 UTC, shares in Probiotec are trading at AU$2.98. This share price information is delayed by 15 minutes.
How has the Probiotec share price performed this year?
Shares in Probiotec last closed at AU$2.98 and the price had moved by +15.17% over the past 365 days. In terms of relative price strength the Probiotec share price has outperformed the ASX All Ordinaries Index by +8.58% over the past year.
What are the analyst and broker recommendations for Probiotec?
The overall consensus recommendation for Probiotec is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Probiotec dividend yield?
The Probiotec dividend yield is 2.35% based on the trailing twelve month period.
Does Probiotec pay a dividend?
Last year, Probiotec paid a total dividend of AU$0.07, and it currently has a trailing dividend yield of 2.35%.Looking ahead, the next dividend pay date is 2024-06-18.
When does Probiotec next pay dividends?
We do not have data on when Probiotec is to next pay dividends. The historic dividend yield on Probiotec shares is currently 2.35%.
How do I buy Probiotec shares?
To buy shares in Probiotec you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Probiotec?
As of the previous close price of AU$2.98, shares in Probiotec had a market capitalisation of AU$242.34m.
Where are Probiotec shares listed?
Here are the trading details for Probiotec:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PBP
What kind of share is Probiotec?
Based on an overall assessment of its quality, value and momentum Probiotec is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Probiotec share price forecast for 2024?
The analyst consensus target price for shares in Probiotec is AU$3.00. That is 0.67% above the last closing price of AU$2.98.
Analysts covering Probiotec currently have a consensus Earnings Per Share (EPS) forecast of AU$0.18 for the next financial year.
Find out moreWhat is the trend in the Probiotec share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Probiotec. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +30.5%.
As of the last closing price of AU$2.98, shares in Probiotec were trading +11.18% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Probiotec PE Ratio?
The Probiotec PE ratio based on its reported earnings over the past 12 months is 14.95. The shares last closed at AU$2.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Probiotec?
Probiotec's management team is headed by:
- Jonathan Wenig - CHM
- Wesley Stringer - CEO
- Jared Stringer - CFO
- Mark Chatfield - GMG
- Dustin Stringer - GMG
- Humera Ahmad - OTH
- Scott Patterson - OTH
- Simon Gray - NID